Pfizer Aktie News

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.

A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $10 billion deal from Novo Nordisk.

Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.

Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer multiple growth pathways, even if the Metsera acquisition turns out to be unsuccessful. The GLP-1 market's increasing competition and pricing pressures may weigh on PFE sentiment, but strong free cash...

Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.

Management lowers full-year guidance, warns about competition, launches bid for Metsera.

Dividend stocks have more than doubled the average annual return of non-payers over the last 51 years. Phenomenal deals can be found among ultra-high-yield dividend stocks -- those with yields four or more times higher than the average yield of the S&P 500.

Pfizer Inc. ( PFE ) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO David Denton - Executive VP & CFO Aamir Malik Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Conference Cal...